CHMP takes positive stance at October meeting
This article was originally published in Scrip
The European Union'sCommittee for Medicinal Products for Human Use (CHMP) was clearly in a positive frame of mind as it recommended approval for all the treatments it was assessing at this month's meeting. The committee issued positive opinions on an AstraZeneca influenza vaccine, three generics and adopted indication extensions for three already authorised medicines.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.